ArticleBriefings in bioinformatics2026
CEDR: robust consensus cancer subtyping with multi-omics data via ensemble dimensionality reduction.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Cancer is a highly heterogeneous disease underpinned by complex molecular alterations. Accurate subtyping is critical for guiding personalized treatment and improving clinical outcomes. However, multi-omics data are high-dimensional, noisy, and heterogeneous across platforms, posing major challenges for reliable subtyping. To address this, dimensionality reduction is necessary to capture underlying molecular patterns in a low-dimensional space, facilitating both computational efficiency and biological interpretation. We present Consensus subtyping method with Ensemble Dimensionality Reduction for multi-omics data integration (CEDR), a consensus subtyping framework that integrates complementary linear and nonlinear dimensionality reduction methods with robust clustering and probabilistic ensemble modeling. Different from existing dimensionality reduction techniques, our framework adopts an ensemble learning framework that integrates multiple dimensionality reduction techniques with robust clustering to achieve reliable consensus cancer subtyping. We apply Optimally Tuned Robust Improper Maximum Likelihood Estimator to the concatenated low-dimensional matrix for robust subtyping, and ensemble the result with the Mixture Model for Clustering Ensembles to identify stable subtypes. Across extensive simulations, CEDR consistently outperformed conventional dimensionality reduction-based clustering, the Cluster Of Clusters Analysis (COCA) ensemble strategy, and state-of-the-art multi-omics integration algorithms (SNF and CIMLR) in both accuracy and robustness. Application to clear cell renal cell carcinoma and lower-grade glioma revealed biologically interpretable subtypes characterized by distinctive survival outcomes, pathway activities, and immune infiltration patterns. These findings demonstrate that CEDR provides a powerful and reliable strategy for multi-omics data integration and cancer subtyping, with strong potential for broader applications in high-dimensional multimodal data analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.